RT Journal Article SR Electronic T1 Comparative effectiveness of teriflunomide and dimethyl fumarate JF Neurology JO Neurology FD Lippincott Williams & Wilkins SP e1811 OP e1820 DO 10.1212/WNL.0000000000007314 VO 92 IS 16 A1 Buron, Mathias Due A1 Chalmer, Thor Ameri A1 Sellebjerg, Finn A1 Frederiksen, Jette A1 Góra, Monika Katarzyna A1 Illes, Zsolt A1 Kant, Matthias A1 Mezei, Zsolt A1 Petersen, Thor A1 Rasmussen, Peter Vestergaard A1 Roshanisefat, Homayoun A1 Hassanpour-Kalam-Roudy, Houry A1 Sejbæk, Tobias A1 Tsakiri, Anna A1 Weglewski, Arkadiusz A1 Sorensen, Per Soelberg A1 Magyari, Melinda YR 2019 UL http://n.neurology.org/content/92/16/e1811.abstract AB Objective To compare on-treatment efficacy and discontinuation outcomes in teriflunomide (TFL) and dimethyl fumarate (DMF) in the treatment of relapsing-remitting multiple sclerosis (RRMS) in a real-world setting.Methods We identified all patients starting TFL or DMF from the Danish Multiple Sclerosis Registry and compared on-treatment efficacy outcomes between DMF using TFL, adjusted for clinical baseline variables and propensity score-based methods.Results We included 2,236 patients in the study: 1,469 patients on TFL and 767 on DMF. Annualized relapse rates (ARRs) in TFL and DMF were 0.16 (95% confidence interval [CI] 0.13–0.20) and 0.09 (95% CI 0.07–0.12), respectively. Relapse rate ratio for DMF/TFL was 0.58 (95% CI 0.46–0.73, p < 0.001). DMF had a higher relapse-free survival proportion at 48 months of follow-up (p < 0.05). We observed no difference in Expanded Disability Status Scale score worsening. Discontinuations due to disease breakthrough were 10.2% (95% CI 7.6%–12.8%) and 22.1% (95% CI 19.2%–25.0%) for DMF and TFL, respectively. A subgroup analysis of ARRs in 708 patients with available baseline MRI T2 lesion amount reported similar results after adjustment.Conclusion We found lower ARR, higher relapse-free survival, and lower incidence of discontinuation due to disease breakthrough on treatment with DMF compared with TFL.Classification of evidence This study provides Class II evidence that for patients with RRMS, DMF is more effective in preventing relapses and has lower discontinuation due to disease breakthrough compared with TFL.ARR=annualized relapse rate; CI=confidence interval; CONFIRM=Comparator and an Oral Fumarate in Relapsing–Remitting Multiple Sclerosis; DEFINE=Determination of the Efficacy and Safety of Oral Fumarate in Relapsing–Remitting MS; DMF=dimethyl fumarate; DMSR=Danish Multiple Sclerosis Registry; DMT=disease-modifying therapy; EDSS=Expanded Disability Status Scale; IPTW=inverse probability of treatment weights; MS=multiple sclerosis; OR=odds ratio; RRMS=relapsing-remitting multiple sclerosis; TEMSO=Teriflunomide Multiple Sclerosis Oral; TFL=teriflunomide; TOWER=An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis